Thanks. I tired to works in a few more different difference but I think it would have obscured the hypocracy of big pharma. I used to work as a bench chemist in a major pharmaceutical company before going to graduate school to get my Ph.D. Once the management of big pharma senses a change in the environment by virtue of FDA approval of rATIII, the low cost production of valuable MAbs becomes viable. Then we will see the BP management lemmings shift and rush to get in the action. I was orginally hoping FDA approval of rATIII in the HD indication would do the trick, but am now think it will only begin to open the door. Positive phase II DIC data for rATIII would the trick for the stock price, but it may actually take postive results from Ovation in their phase III for CABG/HR to really shift BP sentiment.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.